List of Figures:
Figure 1. Research Method Flow Chart 12
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 3. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 17
Figure 4. Europe Transcriptomics Market, 2021-2031, $ mn 20
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of Europe Transcriptomics Market 25
Figure 7. Primary Restraints and Impact Factors of Europe Transcriptomics Market 30
Figure 8. Investment Opportunity Analysis 34
Figure 9. Porter’s Fiver Forces Analysis of Europe Transcriptomics Market 37
Figure 10. Breakdown of Europe Transcriptomics Market by Component, 2021-2031, % of Revenue 42
Figure 11. Europe Addressable Market Cap in 2022-2031 by Component, Value ($ mn) and Share (%) 42
Figure 12. Europe Transcriptomics Market by Component: Instruments, 2021-2031, $ mn 43
Figure 13. Europe Transcriptomics Market by Component: Consumables, 2021-2031, $ mn 45
Figure 14. Europe Transcriptomics Market by Component: Software, 2021-2031, $ mn 47
Figure 15. Europe Transcriptomics Market by Component: Services, 2021-2031, $ mn 49
Figure 16. Breakdown of Europe Transcriptomics Market by Technology, 2021-2031, % of Sales Revenue 51
Figure 17. Europe Addressable Market Cap in 2022-2031 by Technology, Value ($ mn) and Share (%) 51
Figure 18. Europe Transcriptomics Market by Technology: Polymerase Chain Reaction (PCR), 2021-2031, $ mn 52
Figure 19. Europe Transcriptomics Market by Technology: Next-Generation Sequencing, 2021-2031, $ mn 54
Figure 20. Europe Transcriptomics Market by Technology: Microarray, 2021-2031, $ mn 56
Figure 21. Europe Transcriptomics Market by Technology: In-Situ Hybridization (ISH), 2021-2031, $ mn 58
Figure 22. Europe Transcriptomics Market by Technology: Gene Regulation Technologies, 2021-2031, $ mn 60
Figure 23. Europe Transcriptomics Market by Technology: Other Technologies, 2021-2031, $ mn 61
Figure 24. Breakdown of Europe Transcriptomics Market by Application, 2021-2031, % of Sales Revenue 63
Figure 25. Europe Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%) 63
Figure 26. Europe Transcriptomics Market by Application: Drug Discovery and Development, 2021-2031, $ mn 64
Figure 27. Europe Transcriptomics Market by Application: Diagnostics, 2021-2031, $ mn 65
Figure 28. Europe Transcriptomics Market by Application: Single Cell Analysis, 2021-2031, $ mn 66
Figure 29. Europe Transcriptomics Market by Application: Gene Expression, 2021-2031, $ mn 67
Figure 30. Europe Transcriptomics Market by Application: Cell Biology, 2021-2031, $ mn 68
Figure 31. Europe Transcriptomics Market by Application: Other Applications, 2021-2031, $ mn 69
Figure 32. Breakdown of Europe Transcriptomics Market by End User, 2021-2031, % of Revenue 71
Figure 33. Europe Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 71
Figure 34. Europe Transcriptomics Market by End User: Academic and Research Institutions, 2021-2031, $ mn 72
Figure 35. Europe Transcriptomics Market by End User: Biotechnology and Biopharmaceutical Companies, 2021-2031, $ mn 73
Figure 36. Europe Transcriptomics Market by End User: Contract Research Organizations (CROs), 2021-2031, $ mn 74
Figure 37. Europe Transcriptomics Market by End User: Other End Users, 2021-2031, $ mn 75
Figure 38. Breakdown of European Transcriptomics Market by Country, 2021 and 2031, % of Revenue 77
Figure 39. Contribution to Europe 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 78
Figure 40. Transcriptomics Market in Germany, 2021-2031, $ mn 79
Figure 41. Transcriptomics Market in U.K., 2021-2031, $ mn 81
Figure 42. Transcriptomics Market in France, 2021-2031, $ mn 83
Figure 43. Transcriptomics Market in Spain, 2021-2031, $ mn 85
Figure 44. Transcriptomics Market in Italy, 2021-2031, $ mn 87
Figure 45. Transcriptomics Market in Netherlands, 2021-2031, $ mn 89
Figure 46. Transcriptomics Market in Rest of Europe, 2021-2031, $ mn 91
Figure 47. Growth Stage of Europe Transcriptomics Industry over the Forecast Period 93
Europe transcriptomics market was valued at $1,479.6 million in 2021 and will grow by 9.9% annually over 2021-2031, driven by the surging demand for personalized medicine, the high demand for diagnostic of inflammatory diseases such as COVID-19, the decrease in the cost of sequencing, the rising application of next-generation sequencing and RNA sequencing in transcriptomics, and the advancement of products launches along with increasing R&D expenditure. Highlighted with 42 tables and 37 figures, this 121-page report “Europe Transcriptomics Market 2021-2031 by Component (Instruments, Consumables, Software, Services), Technology (PCR, Next-Generation Sequencing, Microarray, ISH, Gene Regulation, Others), Application (Drug Discovery and Development, Diagnostics, Single Cell Analysis, Gene Expression, Cell Biology, Others), End User (Academic and Research Institutions, Biotech and Biopharma Companies, CROs, Others), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe transcriptomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe transcriptomics market in every aspect of the classification from perspectives of Component, Technology, Application, End User, and Country. Based on Component, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Instruments • Consumables • Software • Services Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Polymerase Chain Reaction (PCR) • Next-Generation Sequencing • Microarray • In-Situ Hybridization (ISH) • Gene Regulation Technologies • Other Technologies By Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Drug Discovery and Development • Diagnostics • Single Cell Analysis • Gene Expression • Cell Biology • Other Applications By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section. • Academic and Research Institutions • Biotechnology and Biopharmaceutical Companies • Contract Research Organizations (CROs) • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Netherlands • Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Component, Technology and Application over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Selected Key Players: 10x Genomics Agilent Technologies, Inc. ANGLE plc Becton, Dickinson and Company (BD) Bio-Rad Laboratories, Inc. BioSypder, Inc. Bio-Techne Cytiva F. Hoffmann-La Roche Ltd. Fluidigm Corporation GE Healthcare Illumina, Inc. Menarini Silicon Biosystems Merck & Co., Inc. NanoString Pacific Biosciences of California, Inc. PerkinElmer Inc. Promega Corporation Qiagen N. V. Takara Bio Inc. Thermo Fisher Scientific Inc. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More